Eye on Uplbbph as a growth stock
02-05-2014 • About Uplbbph (
$UPLBBPH) • By InTwits
Uplbbph is an attractive growth stock in industry. Its revenue performance, profitability and healthy financial model stands it out vs. other public companies on the market.
Growth story
Uplbbph showed fast growth in the last financial year. Uplbbph's revenue surged on 17.3% in FY2014. EBITDA also increased considerably: 20.3% for the same period.
In the longer period Uplbbph showed fast revenue growth of 23.2% from FY2011 to FY2014 annually. EBITDA surged on 23.0% from FY2011 to FY2014 annually.
Uplbbph ($UPLBBPH) financials for the last 5 years
| mln. INR | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Revenue | 153,409 | 57,607 | 76,713 | 91,857 | 107,709 |
|---|
| Revenue growth, % | | -62.4% | 33.2% | 19.7% | 17.3% |
|---|
| SG&A, % | | | | | |
|---|
| EBITDA | 9,157 | 10,858 | 13,952 | 16,787 | 20,196 |
|---|
| EBITDA growth, % | | 18.6% | 28.5% | 20.3% | 20.3% |
|---|
| EBITDA margin, % | 5.97% | 18.8% | 18.2% | 18.3% | 18.8% |
|---|
| Net Income | 5,262 | 5,576 | 5,556 | 7,746 | 9,498 |
|---|
| Net Income margin, % | 3.43% | 9.68% | 7.24% | 8.43% | 8.82% |
|---|
| |
| CAPEX | 1,255 | 1,518 | 5,689 | 4,762 | 3,647 |
|---|
| CAPEX/Revenue, % | 0.818% | 2.63% | 7.42% | 5.18% | 3.39% |
|---|
| Debt | 23,818 | 14,973 | 31,475 | 39,270 | 28,610 |
|---|
| Cash | 9,945 | 14,745 | 6,960 | 15,432 | 10,161 |
|---|
| Net Debt/EBITDA | 1.5x | 0.0x | 1.8x | 1.4x | 0.9x |
|---|
| |
| ROIC, % | 13.5% | 16.3% | 17.1% | 15.9% | 18.2% |
|---|
| ROE, % | 18.6% | 16.6% | 14.1% | 17.6% | 19.2% |
|---|
Profitability and return on investment
EBITDA growth was supported by margin expansion. Uplbbph's EBITDA margin increased slightly on 0.500 pp from 18.3% to 18.8% in FY2014. If we look for the longer period the company's EBITDA margin didn't change on 0 pp from 18.8% in FY2011 to 18.8% in FY2014.
We call Uplbbph an attractive growth stock as together with the growth it delivers high ROIC at 18.2%. Three years ago it was a bit lower at 16.3%. For the last three years the average ROIC was 17.0%.
The company's Net Income margin increased slightly on 0.400 pp from 8.40% to 8.80% in FY2014. In the longer period Uplbbph showed decline of 0.900 pp from 9.70% in FY2011 to 8.80% in FY2014.
Uplbbph operates at ROE of 19.2%. For the last three years the average ROE was 16.9%.
Capital expenditures (CAPEX)
Uplbbph's CAPEX/Revenue was 3.39% in FY2014. The company showed fast CAPEX/Revenue growth of 0.752 pp from 2.63% in FY2011 to 3.39% in FY2014. Average CAPEX/Revenue for the last three years was 5.33%.
Leverage (Debt)
Having such a fast growth profile Uplbbph keeps low debt level at 0.9x Net Debt/EBITDA. If we look for the longer period Uplbbph showed fast leverage growth of 0.89x from 0.02x in FY2011 to 0.91x in FY2014.
Management team
Jaidev Rajnikant Shroff "Jai" runs Uplbbph as a CEO and Anand Vora is a CFO.
Peers in
Below you can find Uplbbph benchmarking vs. other companies in industry. It's shown for the period of 5 years for the key financial metrics. Each table has median value for all the companies in the industry together with individual financial data of the top-5 companies in the industry by particular financial metric.
Top companies by Revenue growth, %
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Top |
|---|
| Indbulbbph ($INDBULBBPH) | | -54.2% | -3.2% | -6.5% | 33.5% |
| Rilbbph ($RILBBPH) | | 30.5% | 34.9% | 10.8% | 9.4% |
| |
|---|
| Median (2 companies) | | -11.9% | 15.8% | 2.1% | 21.5% |
|---|
| Uplbbph ($UPLBBPH) | | -62.4% | 33.2% | 19.7% | 17.3% |
Top companies by Gross margin, %
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Top |
|---|
| Jenson & Nicholson Financial Services ($JNFSL) | | | 0.0% | 0.0% | 0.0% |
| Bombay Drugs & Pharmas ($BOMDRDM) | | | 0.0% | 0.0% | 0.0% |
| Southern Herbals ($SOUTHNHE) | | | 0.0% | 0.0% | 0.0% |
| Tafnccpeq ($TAFNCCPEQ) | | | 0.0% | 0.0% | 0.0% |
| |
|---|
| Median (4 companies) | | | 0.0% | 0.0% | 0.0% |
|---|
Top companies by EBITDA margin, %
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Top |
|---|
| Indbulbbph ($INDBULBBPH) | -2.8% | 27.9% | 36.7% | 34.6% | 29.5% |
| Rilbbph ($RILBBPH) | 14.8% | 14.2% | 9.7% | 8.3% | 8.1% |
| |
|---|
| Median (2 companies) | 10.5% | 21.0% | 23.2% | 21.5% | 18.8% |
|---|
| Uplbbph ($UPLBBPH) | 6.0% | 18.8% | 18.2% | 18.3% | 18.8% |
Top companies by CAPEX/Revenue, %
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Top |
|---|
| Rilbbph ($RILBBPH) | 11.4% | 12.7% | 4.6% | 7.7% | 13.8% |
| Indbulbbph ($INDBULBBPH) | 13.9% | 201.8% | 2.3% | 1.6% | 1.5% |
| |
|---|
| Median (2 companies) | 7.6% | 107.3% | 3.4% | 4.7% | 7.7% |
|---|
| Uplbbph ($UPLBBPH) | 0.8% | 2.6% | 7.4% | 5.2% | 3.4% |
Top companies by ROIC, %
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Top 5 |
|---|
| Rilbbph ($RILBBPH) | 9.1% | 10.1% | 8.5% | 7.6% | 7.3% |
| Indbulbbph ($INDBULBBPH) | -0.9% | 2.7% | 3.8% | 4.2% | 4.9% |
| Tafnccpeq ($TAFNCCPEQ) | | | 0.0% | 0.0% | 0.0% |
| Jenson & Nicholson Financial Services ($JNFSL) | | | 0.0% | 0.0% | 0.0% |
| Bombay Drugs & Pharmas ($BOMDRDM) | | | 0.0% | 0.0% | 0.0% |
| |
|---|
| Median (9 companies) | 9.2% | 5.4% | 3.8% | 0.0% | 0.0% |
|---|
| Uplbbph ($UPLBBPH) | 13.5% | 16.3% | 17.1% | 15.9% | 18.2% |
Top companies by Net Debt / EBITDA
| FY2010 | FY2011 | FY2012 | FY2013 | FY2014 |
|---|
| Top |
|---|
| Indbulbbph ($INDBULBBPH) | | 8.5x | 4.3x | 4.8x | 5.5x |
| Rilbbph ($RILBBPH) | 1.7x | 1.8x | 1.7x | 2.1x | 2.9x |
| The United Nilgiri Tea Estates Company ($UNITEDTEA) | -0.1x | 0.7x | -0.9x | -0.8x | |
| |
|---|
| Median (3 companies) | -0.1x | 1.2x | 1.7x | 2.1x | 4.2x |
|---|
| Uplbbph ($UPLBBPH) | 1.5x | 0.0x | 1.8x | 1.4x | 0.9x |
